Novel approaches to flavivirus drug discovery

Expert Opinion on Drug Discovery

Volumn 7, Issue 5, 2012, Pages 417-428

  Botting, Carolyn ^a   Kuhn, Richard J ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Antiviral; Compound; Dengue; Inhibitor; Peptide; Small molecule

Indexed keywords

ANTIVIRUS AGENT; CASTANOSPERMINE 6 BUTYRATE; ENVELOPE PROTEIN; LYCORINE; NONSTRUCTURAL PROTEIN 4B; PROTEIN C; VIRUS RNA;

ANTIVIRAL THERAPY; DENGUE; DENGUE VIRUS; DRUG DEVELOPMENT; DRUG TARGETING; ENDOSOME; FLAVIVIRUS; HUMAN; IMMUNE EVASION; INCIDENCE; LIFE CYCLE; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA PROCESSING; SEROTYPE; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; ANTIVIRAL AGENTS; DENGUE VIRUS; DRUG DISCOVERY; FLAVIVIRIDAE; FLAVIVIRUS INFECTIONS; HUMANS; MICE; NANOTUBES; PEPTIDES; PHENANTHRIDINES; RNA, SMALL INTERFERING; RNA, VIRAL; SMALL MOLECULE LIBRARIES; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION; WEST NILE VIRUS; YELLOW FEVER VIRUS;

EID: 84860368072     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.673579     Document Type: Review

References (92)

1. Perry ST, Buck MD, Shresta S. Better late than never: Antivirals for dengue. Expert Rev Anti Infect Ther 2011;9(7):755-7
2. Gubler D, Kuno G, Markoff L. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Volume 1 5th edition. Lippincott William & Wilkins; Philadelphia, PA: 2007. p. 1153-1253
3. Watanaveeradej V, Simasathien S, Nisalak A, et al. Safety and immunogenicity of a tetravalent live-Attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 2011;85(2):341-51
4. Rumyantsev AA, Giel-Moloney M, Liu YX, et al. Characterization of the RepliVax platform for replication-defective flavivirus vaccines. Vaccine 2011;29(32):5184-94
5. Gollins SW, Porterfield JS. Flavivirus infection enhancement in macrophages - Radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol 1984;65:1261-72 (Pubitemid 14096940)
6. Gollins SW, Porterfield JS. Flavivirus infection enhancement in macrophages - An electron-microscopic study of viral cellular entry. J Gen Virol 1985;66:1969-82 (Pubitemid 16251099)
7. Lin CC, Philips L, Xu C, et al. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004;44(3):265-75 (Pubitemid 38236158)
8. Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment - Finding the right path. Nat Rev Drug Discov 2007;6(12):991-1000 (Pubitemid 350201789)
9. Li L, Lok SM, Yu IM, et al. The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science 2008;319(5871):1830-4 (Pubitemid 351451591)
10. Patkar CG, Jones CT, Chang YH, et al. Functional requirements of the yellow fever virus capsid protein. J Virol 2007;81(12):6471-81 (Pubitemid 46878052)
11. Lin YJ, Wu SC. Histidine at residue 99 and the transmembrane region of the precursor membrane prM protein are important for the prM-E heterodimeric complex formation of Japanese encephalitis virus. J Virol 2005;79(13):8535-44
12. Smit JM, Moesker B, Rodenhuis-Zybert I, et al. Flavivirus cell entry and membrane fusion. Viruses Basel 2011;3(2):160-71
13. Avirutnan P, Hauhart RE, Somnuke P, et al. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol 2011;Jul187(1):424-33
14. Avirutnan P, Fuchs A, Hauhart RE, et al. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med 2010;207(4):793-806
15. Chung KM, Liszewski MK, Nybakken G, et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci USA 2006;103(50):19111-16 (Pubitemid 350002836)
16. Wen JL, Hua BC, Xiang JW, et al. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J Virol 2004;78(22):12225-35 (Pubitemid 39458742)
17. Liu WJ, Chen HB, Khromykh AA. Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J Virol 2003;77(14):7804-13 (Pubitemid 36792777)
18. Kummerer BM, Rice CM. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol 2002;76(10):4773-84 (Pubitemid 34441683)
19. Chambers TJ, Weir RC, Grakoui A, et al. Evidence that the N-Terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci USA 1990;87(22):8898-902 (Pubitemid 120007616)
20. Roosendaal J, Westaway EG, Khromykh A, et al. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and golgi trafficking of the NS4A protein. J Virol 2006;80(9):4623-32
21. Ambrose RL, Mackenzie JM. West Nile virus differentially modulates the unfolded protein response to facilitate replication and immune evasion. J Virol 2011;85(6):2723-32
22. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005;79(13):8004-13 (Pubitemid 40853504)
23. Grant D, Tan GK, Qing M, et al. A Single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis. J Virol 2011;85(15):7775-87
24. Dong HP, Zhang B, Shi PY. Flavivirus methyltransferase: A novel antiviral target. Antiviral Res 2008;80(1):1-10
25. Iglesias NG, Filomatori CV, Gamarnik AV. The F1 motif of dengue virus polymerase NS5 is involved in promoter-dependent RNA synthesis. J Virol 2011;85(12):5745-56
26. Issur M, Geiss BJ, Bougie I, et al. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA 2009;15(12):2340-50
27. Zhang N, Chen HM, Koch V, et al. Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against Flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J Med Chem 2003;46(19):4149-64 (Pubitemid 37122457)
28. Ray D, Shi P-Y. Recent advances in flavivirus antiviral drug discovery and vaccine development. Recent Patents Anti Infect Drug Discov 2006;1(1):45-55
29. Ishak R, Tovey DG, Howard CR. Morphogenesis of yellow fever virus 17D in infected cell cultures. J Gen Virol 1988;69:325-35 (Pubitemid 18064164)
30. van der Schaar HM, Rust MJ, Waarts B-L, et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 2007;81(21):12019-28 (Pubitemid 47623832)
31. Bressanelli S, Stiasny K, Allison SL, et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. Embo J 2004;23(4):728-38 (Pubitemid 38425440)
32. Modis Y, Ogata S, Clements D, et al. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003;100(12):6986-91 (Pubitemid 36706380)
33. Nemesio H, Palomares-Jerez F, Villalain J. The membrane-Active regions of the dengue virus proteins C and E. Biochim Biophys Acta Biomembr 2011;1808(10):2390-402
34. Mackenzie JM, Khromykh AA, Westaway EG. Stable expression of noncytopathic Kunjin replicons simulates both ultrastructural and biochemical characteristics observed during replication of Kunjin virus. Virology 2001;279(1):161-72 (Pubitemid 34161008)
35. Elshuber S, Allison SL, Heinz FX, et al. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol 2003;84:183-91 (Pubitemid 36113564)
36. Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell 2002;108(5):717-25 (Pubitemid 34241430)
37. Li L, Lok SM, Yu IM, et al. The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science 2008;319(5871):1830-4 (Pubitemid 351451591)
38. Modis Y, Ogata S, Clements D, et al. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004;427(6972):313-19 (Pubitemid 38133652)
39. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005;3(1):13-22 (Pubitemid 40028466)
40. Stadler K, Allison SL, Schalich J, et al. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 1997;71(11):8475-81 (Pubitemid 27446428)
41. Yu IM, Zhang W, Holdaway HA, et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008;319(5871):1834-7 (Pubitemid 351451592)
42. Zhang W, Chipman PR, Corver J, et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 2003;10(11):907-12 (Pubitemid 37386099)
43. Perera R, Khaliq M, Kuhn RJ. Closing the door on flaviviruses: Entry as a target for antiviral drug design. Antiviral Res 2008;80(1):11-22
44. Poh MK, Yip A, Zhang S, et al. A small molecule fusion inhibitor of dengue virus. Antiviral Res 2009;84(3):260-6
45. Wang Q-Y, Patel SJ, Vangrevelinghe E, et al. A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother 2009;53(5):1823-31
46. Altmeyer R. Virus attachment and entry offer numerous targets for antiviral therapy. Curr Pharm Des 2004;10(30):3701-12 (Pubitemid 39409864)
47. Yennamalli R, Subbarao N, Kampmann T, et al. Identification of novel target sites and an inhibitor of the dengue virus E protein. J Comput Aided Mol Des 2009;23(6):333-41
48. Li Z, Khaliq M, Zhou Z, et al. Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J Med Chem 2008;51(15):4660-71
49. Mayhoub AS, Khaliq M, Kuhn RJ, et al. Design, synthesis, and biological evaluation of thiazoles targeting flavivirus envelope proteins. J Med Chem 2011;54(6):1704-14
50. Zhou Z, Khaliq M, Suk J-E, et al. Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem Biol 2008;3(12):765-75
51. Kampmann T, Yennamalli R, Campbell P, et al. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antiviral Res 2009;84(3):234-41
52. Allison SL, Stiasny K, Stadler K, et al. Mapping of functional elements in the stem-Anchor region of tick-borne encephalitis virus envelope protein E. J Virol 1999;73(7):5605-12 (Pubitemid 29274844)
53. Schmidt AG, Yang PL, Harrison SC. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS Pathog 2010;6(4):e1000851
54. Schmidt AG, Yang PL, Harrison SC. Peptide inhibitors of flavivirus entry derived from the E protein stem. J Virol 2010;84(24):12549-54
55. Costin JM, Jenwitheesuk E, Lok S-M, et al. Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl Trop Dis 2010;4:(6):e721.
56. Nicholson CO, Costin JM, Rowe DK, et al. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro. Antiviral Res 2011;89(1):71-4
57. Tarallo R, Accardo A, Falanga A, et al. Clickable functionalization of liposomes with the gH625 peptide from herpes simplex virus type 1 for intracellular drug delivery. Chemistry (Easton) 2011;17(45):12659-68
58. Dartois V, Sanchez-Quesada J, Cabezas E, et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother 2005;49(8):3302-10 (Pubitemid 41060575)
59. Fernandez-Lopez S, Kim HS, Choi EC, et al. Antibacterial agents based on the cyclic D,L-Alpha-peptide architecture. Nature 2001;412(6845):452-5 (Pubitemid 32702711)
60. Fletcher JT, Finlay JA, Callow ME, et al. A combinatorial approach to the discovery of biocidal six-residue cyclic D, L-Alpha-peptides against the bacteria methicillin-resistant staphylococcus aureus (MRSA) and E-coli and the biofouling algae ulva linza and navicula perminuta. Chem Eur J 2007;13(14):4008-13 (Pubitemid 46925610)
61. Horne WS, Wiethoff CM, Cui CL, et al. Antiviral cyclic D,L-Alpha-peptides: Targeting a general biochemical pathway in virus infections. Bioorg Med Chem 2005;13(17):5145-53 (Pubitemid 41039973)
62. Montero A, Gastaminza P, Law M, et al. Self-Assembling peptide nanotubes with antiviral activity against hepatitis C virus. Chem Biol 2011;18(11):1453-62
63. Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 2005;79(8):4599-609 (Pubitemid 40464211)
64. Kinney RM, Huang CYH, Rose BC, et al. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J Virol 2005;79(8):5116-28 (Pubitemid 40464261)
65. Holden KL, Stein DA, Pierson TC, et al. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3'stem-loop structure. Virology 2006;344(2):439-52 (Pubitemid 43049631)
66. Achazi K, Patel P, Paliwal R, et al. RNA interference inhibits replication of tick-borne encephalitis virus in vitro. Antiviral Res 2012;93(1):94-100
67. Pacca CC, Severino AA, Mondini A, et al. RNA interference inhibits yellow fever virus replication in vitro and in vivo. Virus Genes 2009;38(2):224-31
68. Ivacik D, Ely A, Arbuthnot P. Countering hepatitis B virus infection using RNAi: How far are we from the clinic? Rev Med Virol 2011;21(6):383-96
69. Ieven M, Vlietinck AJ, Vandenberghe DA, et al. Plant antiviral agents. 3. Isolation of alkaloids from clivia-minata regel (Amaryllidaceae). J Nat Prod 1982;45(5):564-73 (Pubitemid 13142609)
70. Li SY, Chen C, Zhang HQ, et al. Identification of natural compounds with antiviral activities against SARS-Associated coronavirus. Antiviral Res 2005;67(1):18-23 (Pubitemid 40798914)
71. Renardnozaki J, Kim T, Imakura Y, et al. Effect of alkaloids isolated from Amaryllidaceae on herpes-simplex virus. Res Virol 1989;140(2):115-28 (Pubitemid 19116159)
72. Liu J, Yang Y, Xu Y, et al. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J 2011;8:483-92
73. Zou G, Puig-Basagoiti F, Zhang B, et al. A single-Amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 2009;384(1):242-52
74. Mertens E, Kajaste-Rudnitski A, Torres S, et al. Viral determinants in the NS3 helicase and 2K peptide that promote West Nile virus resistance to antiviral action of 2',5'-oligoadenylate synthetase 1b. Virology 2010;399(1):176-85
75. Miller S, Kastner S, Krijnse-Locker J, et al. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J Biol Chem 2007;282(12):8873-82 (Pubitemid 47093477)
76. Miller S, Sparacio S, Bartenschlager R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J Biol Chem 2006;281(13):8854-63 (Pubitemid 43847992)
77. Patkar CG, Larsen M, Owston M, et al. Identification of inhibitors of yellow fever virus replication using a replicon-based high-Throughput assay. Antimicrob Agents Chemother 2009;53(10):4103-14
78. Xie X, Wang Q-Y, Xu HY, et al. Inhibition of dengue virus by targeting viral NS4B protein. J Virol 2011;85(21):11183-95
79. Umareddy I, Chao A, Sampath A, et al. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J Gen Virol 2006;87:2605-14
80. Ong SP, Chu JJH, Ng ML. Inhibition of West Nile virus replication in cells stably transfected with vector-based shRNA expression system. Virus Res 2008;135(2):292-7
81. Qin CF, Qin ED. Capsid-Targeted viral inactivation can destroy dengue 2 virus from within in vitro. Arch Virol 2006;151(2):379-85
82. Lopez C, Gil L, Lazo L, et al. In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol 2009;154(4):695-8
83. Molyneux RJ, Roitman JN, Dunnheim G, et al. 6-Epicatanospermine, a novel indolizidine alkaloid that inhibits alpha-glucosidase. Arch Biochem Biophys 1986;251(2):450-7 (Pubitemid 17234242)
84. Kang MS. Uptake and metabolism of BuCast: A glycoprotein processing inhibitor and a potential anti-HIV drug. Glycobiology 1996;6(2):209-16 (Pubitemid 26139063)
85. Taylor DL, Sunkara PS, Liu PS, et al. 6-0-Butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIV. Aids 1991;5(6):693-8
86. Rathore APS, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 2011;92(3):453-60
87. Somnuke P, Hauhart RE, Atkinson JP, et al. N-linked glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with human complement. Virology 2011;413(2):253-64
88. Heaton NS, Perera R, Berger KL, et al. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci USA 2010;107(40):17345-50
89. Dengue virus perturbs lipid metabolism in infected mosquito cells.
90. Perera R, Riley C, Hopf-Jannasch AS, et al. Dengue virus perturbs lipid metabolism in infected mosquito cells. PLoS Pathog 2012; In press 90. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005;3(1):13-22 (Pubitemid 40028466)
91. Miller S, Krijnse-Locker J. Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol 2008;6(5):363-74 (Pubitemid 351552657)
92. Quinkert D, Bartenschlager R, Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J Virol 2005;79(21):13594-605 (Pubitemid 41508172)